FY2026 EPS Forecast for Perspective Therapeutics Lowered by Analyst

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Brookline Capital Markets decreased their FY2026 earnings estimates for Perspective Therapeutics in a research note issued to investors on Tuesday, November 10th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will earn ($1.00) per share for the year, down from their previous forecast of ($0.99). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.98) per share. Brookline Capital Markets also issued estimates for Perspective Therapeutics’ Q4 2026 earnings at ($0.25) EPS.

Several other research analysts have also issued reports on CATX. Piper Sandler reduced their price target on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a report on Friday, October 30th. Wedbush reissued an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday. Bank of America reduced their target price on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Friday, August 14th. Finally, William Blair initiated coverage on Perspective Therapeutics in a report on Friday, September 18th. They set an “outperform” rating on the stock. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.10.

Perspective Therapeutics Stock Performance

Shares of Perspective Therapeutics stock opened at $0.83 on Thursday. The firm has a fifty day moving average of $2.20 and a two-hundred day moving average of $3.46. The company has a current ratio of 5.18, a quick ratio of 6.61 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 52 week low of $0.78 and a 52 week high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds have recently bought and sold shares of CATX. Voya Investment Management LLC increased its position in shares of Perspective Therapeutics by 34.4% in the 3rd quarter. Voya Investment Management LLC now owns 453,650 shares of the company’s stock valued at $1,248,000 after buying an additional 116,149 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Perspective Therapeutics by 53.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after buying an additional 21,150 shares during the period. Provenance Wealth Advisors LLC acquired a new stake in Perspective Therapeutics during the 3rd quarter worth $44,000. Auctus Advisors LLC raised its stake in Perspective Therapeutics by 83.6% during the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after buying an additional 17,015 shares during the period. Finally, Taylor & Morgan Wealth Management LLC lifted its holdings in Perspective Therapeutics by 30.3% during the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after acquiring an additional 20,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.